The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons ...

Biomedical engineer Nenad Bursac, standing, and postdoctoral associate Tianyu Wu image a heart tissue patch through a microscope at the Bursac lab at the Duke University Pratt School of Engineering.

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...

Fractyl Health announced a first-in-human trial for RJVA-001, targeting T2D and obesity, pending regulatory approval by 2026. Fractyl Health, Inc. has announced the submission of the first module of ...

The search for gene therapies to treat rheumatoid arthritis (RA) has moved in fits and starts over the past two decades, with trials starting and stopping, and their focus shifting to osteoarthritis ...

RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking preclinical research that supports a nearly ...

New research found that gene therapy for children with "bubble boy disease," or SCID, was successful in 95% of trial ...